PLACES ARE LIMITED TO 40 PARTICIPANTS.
At the end of these conferences, participant will be able to:
Pneumococcal vaccination: Lowering the risk Invasive pneumococcal disease Ambulatory treatment of COVID-19
1. Cite the evidence demonstrating risk reduction following pneumococcal vaccination;
2. Identify populations younger than 65 who will benefit from pneumococcal vaccination;
3. Elaborate on the landscape of pneumococcal vaccination available;
4. Cite the recommendations of the PIQ and as well as the CDC on pneumococcal vaccination and the choices available to our patients including in patients who have had pneumococcal vaccinations prior to the age of 65;
5. Evaluate the app PneumoRecs Vax Advisor of the Advisory Committee of Immunization Practices (ACIP) of the CDC as tool to help assess pneumococcal vaccination recommendations;
6. Identify patients suffering with COVID-19 symptoms that can benefit from antiviral therapy and highlight common medication interactions with antivirals.
Optimizing cardiovascular risk reduction treatment in 2023: focus on nHDL and implication of serum triglycerides in high risk individuals
1. Risk stratify patients to identify who will benefit from lipid lowering for CVD reduction;
2. Define in nHDL values as thresholds for initiating statins and treatment targets for cardiovascular risk reduction;
3. Learn the concept of looking beyond nHDL in high risk patients with TAG > 1.5 for further interventions beyond lipid lowering;
4. Cite the evidence of NAFLD as a risk factor for cirrhosis as well as CVD and learn how to counsel patients.
Moderator : Dr. Jonathan Singerman. Conferences given by Drs. Karl Weiss and Dr Morris Schweitzer.
From 17 h 30 to 17 h 45, Welcome
From 17 h 45 to 18 h 15, Meal
From 18 h 15 to 19 h 45, Conference
From 19 h 45 to 19 h 55, Break
From 19 h 55 to 21 h 25, Conference
This conference will be held at La Sirène de la Mer restaurant, located at 114 Dresden Ave., Mont-Royal, QC H3P 2B6.
The AMOM recommends that all participants follow the provincial health guidelines related to the COVID-19 pandemic.
Participants acknowledge and accept the health risks that may be associated with in-person participation and understand that they are solely responsible for assessing their own health and taking appropriate safety measures for their situation.
An attendance list can be sent to the pharmaceutical company after the activity, if requested. By this registration, the general practitioner and/or any other healthcare professional consents to the disclosure of his first and last name to the pharmaceutical company.
The pharmaceutical company agrees not to communicate this information without the consent of the participant.
If you do not want your first and last name disclosed, please contact Ms. Aline Sabbagh at firstname.lastname@example.org indicating the activity number.
Recognition of Educational Activities
L’Association des médecins omnipraticiens de Montréal, under the aegis of the FMOQ, recognizes 3.00 hours of professional development activity, of category 1, as required by the professional development regulations of the CMQ. The FMOQ number to retrieve your certificate is 85650.
This activity has received an educational subsidy from Pfizer Canada.